Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.

Bhide Y, Dong W, Gribonika I, Voshart D, Meijerhof T, de Vries-Idema J, Norley S, Guilfoyle K, Skeldon S, Engelhardt OG, Boon L, Christensen D, Lycke N, Huckriede A.

Front Immunol. 2019 Mar 29;10:646. doi: 10.3389/fimmu.2019.00646. eCollection 2019.

2.

No significant HTLV seroprevalence in German people who inject drugs.

Hohn O, Norley S, Kücherer C, Bazarbachi A, El Hajj H, Marcus U, Zimmermann R, Bannert N.

PLoS One. 2017 Aug 22;12(8):e0183496. doi: 10.1371/journal.pone.0183496. eCollection 2017.

3.

Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.

van Doorn E, Pleguezuelos O, Liu H, Fernandez A, Bannister R, Stoloff G, Oftung F, Norley S, Huckriede A, Frijlink HW, Hak E.

BMC Infect Dis. 2017 Apr 4;17(1):241. doi: 10.1186/s12879-017-2341-9.

4.

Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol.

van Doorn E, Liu H, Ben-Yedidia T, Hassin S, Visontai I, Norley S, Frijlink HW, Hak E.

Medicine (Baltimore). 2017 Mar;96(11):e6339. doi: 10.1097/MD.0000000000006339.

5.

The Human Antimicrobial Protein Bactericidal/Permeability-Increasing Protein (BPI) Inhibits the Infectivity of Influenza A Virus.

Pinkenburg O, Meyer T, Bannert N, Norley S, Bolte K, Czudai-Matwich V, Herold S, Gessner A, Schnare M.

PLoS One. 2016 Jun 6;11(6):e0156929. doi: 10.1371/journal.pone.0156929. eCollection 2016.

6.

Development of an antigen-capture ELISA for the detection of the p27-CA protein of HERV-K(HML-2).

Hohn O, Mostafa S, Norley S, Bannert N.

J Virol Methods. 2016 Aug;234:186-92. doi: 10.1016/j.jviromet.2016.04.016. Epub 2016 Apr 30.

PMID:
27142113
7.

Suppressing active replication of a live attenuated simian immunodeficiency virus vaccine does not abrogate protection from challenge.

Gabriel B, Fiebig U, Hohn O, Plesker R, Coulibaly C, Cichutek K, Mühlebach MD, Bannert N, Kurth R, Norley S.

Virology. 2016 Feb;489:1-11. doi: 10.1016/j.virol.2015.11.030. Epub 2015 Dec 11.

8.

Assessment of ambiguous base calls in HIV-1 pol population sequences as a biomarker for identification of recent infections in HIV-1 incidence studies.

Meixenberger K, Hauser A, Jansen K, Yousef KP, Fiedler S, von Kleist M, Norley S, Somogyi S, Hamouda O, Bannert N, Bartmeyer B, Kücherer C.

J Clin Microbiol. 2014 Aug;52(8):2977-83. doi: 10.1128/JCM.03289-13. Epub 2014 Jun 11.

9.

Timed action of IL-27 protects from immunopathology while preserving defense in influenza.

Liu FD, Kenngott EE, Schröter MF, Kühl A, Jennrich S, Watzlawick R, Hoffmann U, Wolff T, Norley S, Scheffold A, Stumhofer JS, Saris CJ, Schwab JM, Hunter CA, Debes GF, Hamann A.

PLoS Pathog. 2014 May 8;10(5):e1004110. doi: 10.1371/journal.ppat.1004110. eCollection 2014 May.

10.

A novel small animal model to study the replication of simian foamy virus in vivo.

Blochmann R, Curths C, Coulibaly C, Cichutek K, Kurth R, Norley S, Bannert N, Fiebig U.

Virology. 2014 Jan 5;448:65-73. doi: 10.1016/j.virol.2013.09.027. Epub 2013 Oct 18.

11.

HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: Gene gun is superior to jet injector in inducing CTL responses and protective immunity.

Nguyen-Hoai T, Kobelt D, Hohn O, Vu MD, Schlag PM, Dörken B, Norley S, Lipp M, Walther W, Pezzutto A, Westermann J.

Oncoimmunology. 2012 Dec 1;1(9):1537-1545.

12.

CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.

Nguyen-Hoai T, Hohn O, Vu MD, Baldenhofer G, Sayed Ahmed MS, Dörken B, Norley S, Lipp M, Pezzutto A, Westermann J.

Cancer Gene Ther. 2012 Dec;19(12):880-7. doi: 10.1038/cgt.2012.78. Epub 2012 Oct 26.

PMID:
23099886
13.

Characterization of a monoclonal anti-capsid antibody that cross-reacts with three major primate lentivirus lineages.

Sanders-Beer BE, Eschricht M, Seifried J, Hirsch VM, Allan JS, Norley S.

Virology. 2012 Jan 20;422(2):402-12. doi: 10.1016/j.virol.2011.11.003. Epub 2011 Dec 5.

14.

Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene.

Soprana E, Panigada M, Knauf M, Radaelli A, Vigevani L, Palini A, Villa C, Malnati M, Cassina G, Kurth R, Norley S, Siccardi AG.

J Virol Methods. 2011 Jun;174(1-2):22-8. doi: 10.1016/j.jviromet.2011.03.013. Epub 2011 Mar 16.

PMID:
21419167
15.

Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV).

Sipo I, Knauf M, Fechner H, Poller W, Planz O, Kurth R, Norley S.

Vaccine. 2011 Feb 11;29(8):1690-9. doi: 10.1016/j.vaccine.2010.12.037. Epub 2010 Dec 30.

PMID:
21195079
16.

Codon-optimization of the hemagglutinin gene from the novel swine origin H1N1 influenza virus has differential effects on CD4(+) T-cell responses and immune effector mechanisms following DNA electroporation in mice.

Tenbusch M, Grunwald T, Niezold T, Storcksdieck Genannt Bonsmann M, Hannaman D, Norley S, Uberla K.

Vaccine. 2010 Apr 26;28(19):3273-7. doi: 10.1016/j.vaccine.2010.02.090. Epub 2010 Mar 4.

PMID:
20206668
17.

SIVagm containing the SHIV89.6P Envelope gene replicates poorly and is non-pathogenic.

Perković M, Norley S, Sanzenbacher R, Battenberg M, Panitz S, Coulibaly C, Flory E, Siegismund C, Münk C, Cichutek K.

Virology. 2010 Mar 30;399(1):87-97. doi: 10.1016/j.virol.2009.12.032. Epub 2010 Jan 25.

18.
19.

Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors.

Falkensammer B, Rubner B, Hiltgartner A, Wilflingseder D, Stahl Hennig C, Kuate S, Uberla K, Norley S, Strasak A, Racz P, Stoiber H.

Retrovirology. 2009 Jun 21;6:60. doi: 10.1186/1742-4690-6-60.

20.

A neutralization assay for HIV-2 based on measurement of provirus integration by duplex real-time PCR.

Behrendt R, Fiebig U, Norley S, Gürtler L, Kurth R, Denner J.

J Virol Methods. 2009 Jul;159(1):40-6. doi: 10.1016/j.jviromet.2009.02.024. Epub 2009 Mar 4.

PMID:
19442843
21.

Accelerated prion replication in, but prolonged survival times of, prion-infected CXCR3-/- mice.

Riemer C, Schultz J, Burwinkel M, Schwarz A, Mok SW, Gültner S, Bamme T, Norley S, van Landeghem F, Lu B, Gerard C, Baier M.

J Virol. 2008 Dec;82(24):12464-71. doi: 10.1128/JVI.01371-08. Epub 2008 Oct 8.

22.

Characterization of a chemokine receptor CCR5-negative T cell line and its use in determining human immunodeficiency virus type 1 phenotype.

Binninger-Schinzel D, Müller D, Wolf T, Krause B, Meye B, Winskowsky G, Raupp S, Norley S, Brodt R, Werner A.

J Med Virol. 2008 Feb;80(2):192-200.

PMID:
18098144
23.

Atraumatic oral spray immunization with replication-deficient viral vector vaccines.

Stahl-Hennig C, Kuate S, Franz M, Suh YS, Stoiber H, Sauermann U, Tenner-Racz K, Norley S, Park KS, Sung YC, Steinman R, Racz P, Uberla K.

J Virol. 2007 Dec;81(23):13180-90. Epub 2007 Sep 26.

24.

Preparation and characterization of new challenge stocks of SIVmac32H J5 following rapid serial passage of virus in vivo.

Ferguson D, Wade-Evans A, Elsley W, Sangster R, Silvera P, MacManus S, Davis G, Corcoran T, Berry N, Brown S, Jenkins A, Cowie J, Sethi M, Hull R, Stebbings R, Lines J, Norley S, Stott EJ, Almond N.

J Med Primatol. 2007 Jun;36(3):131-42.

PMID:
17517087
25.

Sustained conservation of CD4+ T cells in multiprotein triple modality-immunized rhesus macaques after intrarectal challenge with simian immunodeficiency virus.

Stolte-Leeb N, Sauermann U, Norley S, Fagrouch Z, Heeney J, Franz M, Hunsmann G, Stahl-Hennig C.

Viral Immunol. 2006 Summer;19(3):448-57.

PMID:
16987063
26.

Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus.

Kuate S, Stahl-Hennig C, Stoiber H, Nchinda G, Floto A, Franz M, Sauermann U, Bredl S, Deml L, Ignatius R, Norley S, Racz P, Tenner-Racz K, Steinman RM, Wagner R, Uberla K.

Virology. 2006 Jul 20;351(1):133-44. Epub 2006 Apr 17.

27.

Retroviral vectors for vaccine development: induction of HIV-1-specific humoral and cellular immune responses in rhesus macaques using a novel MLV(HIV-1) pseudotype vector.

Neumann J, Stitz J, König R, Seibold E, Norley S, Flory E, Cichutek K.

J Biotechnol. 2006 Jul 25;124(3):615-25. Epub 2006 Mar 24.

PMID:
16563543
28.

Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.

Suh YS, Park KS, Sauermann U, Franz M, Norley S, Wilfingseder D, Stoiber H, Fagrouch Z, Heeney J, Hunsmann G, Stahl-Hennig C, Sung YC.

Vaccine. 2006 Mar 10;24(11):1811-20. Epub 2005 Oct 25.

PMID:
16274888
29.

T-cell-mediated protective efficacy of a systemic vaccine approach in cynomolgus monkeys after SIV mucosal challenge.

Michelini Z, Negri DR, Baroncelli S, Catone S, Comini A, Maggiorella MT, Sernicola L, Crostarosa F, Belli R, Mancini MG, Farcomeni S, Fagrouch Z, Ciccozzi M, Rovetto C, Liljestrom P, Norley S, Heeney J, Titti F.

J Med Primatol. 2004 Oct;33(5-6):251-61.

PMID:
15525326
30.

Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens.

Koopman G, Mortier D, Hofman S, Niphuis H, Fagrouch Z, Norley S, Sutter G, Liljeström P, Heeney JL.

J Gen Virol. 2004 Oct;85(Pt 10):2915-24.

PMID:
15448353
31.

[Conference on vaccine development and innovative therapy concepts in HIV/AIDS at the Robert Koch Institute].

Norley S.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004 Mar;47(3):288-90. German. No abstract available.

PMID:
15205798
32.

Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge.

Negri DR, Baroncelli S, Catone S, Comini A, Michelini Z, Maggiorella MT, Sernicola L, Crostarosa F, Belli R, Mancini MG, Farcomeni S, Fagrouch Z, Ciccozzi M, Boros S, Liljestrom P, Norley S, Heeney J, Titti F.

J Gen Virol. 2004 May;85(Pt 5):1191-201.

PMID:
15105535
33.

The role of the immune response during SIVagm infection of the African green monkey natural host.

Norley S, Kurth R.

Front Biosci. 2004 Jan 1;9:550-64. Review.

PMID:
14766390
34.

PDZ Domain-mediated interaction of interleukin-16 precursor proteins with myosin phosphatase targeting subunits.

Bannert N, Vollhardt K, Asomuddinov B, Haag M, König H, Norley S, Kurth R.

J Biol Chem. 2003 Oct 24;278(43):42190-9. Epub 2003 Aug 14.

35.

Prion diseases: infectious and lethal doses following oral challenge.

Baier M, Norley S, Schultz J, Burwinkel M, Schwarz A, Riemer C.

J Gen Virol. 2003 Jul;84(Pt 7):1927-9.

PMID:
12810889
36.

Vaccine development using the simian immunodeficiency virus model for AIDS.

Norley S, Beer B, Binninger-Schinzel D, Vogel T, Hohn O, Seibold E, Radke D, Cosma C, Kurth R.

Intervirology. 2002;45(4-6):267-74.

PMID:
12566709
37.

Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes.

König RR, Flory E, Steidl S, Neumann J, Coulibaly C, Holznagel E, Holzammer S, Norley S, Cichutek K.

J Virol. 2002 Nov;76(21):10627-36.

38.
40.
41.
42.

Effect of vaccination with recombinant modified vaccinia virus Ankara expressing structural and regulatory genes of SIV(macJ5) on the kinetics of SIV replication in cynomolgus monkeys.

Negri DR, Baroncelli S, Michelini Z, Macchia I, Belli R, Catone S, Incitti F, ten Haaft P, Corrias F, Cranage MP, Polyanskaya N, Norley S, Heeney J, Verani P, Titti F.

J Med Primatol. 2001 Aug;30(4):197-206.

PMID:
11555138
43.

High virus loads in naturally and experimentally SIVagm-infected African green monkeys.

Holzammer S, Holznagel E, Kaul A, Kurth R, Norley S.

Virology. 2001 May 10;283(2):324-31.

44.

Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes.

Mathy NL, Scheuer W, Lanzendörfer M, Honold K, Ambrosius D, Norley S, Kurth R.

Immunology. 2000 May;100(1):63-9.

45.

Cutting edge: CD4 is not required for the functional activity of IL-16.

Mathy NL, Bannert N, Norley SG, Kurth R.

J Immunol. 2000 May 1;164(9):4429-32.

46.

Two distinct gamma-2 herpesviruses in African green monkeys: a second gamma-2 herpesvirus lineage among old world primates?

Greensill J, Sheldon JA, Renwick NM, Beer BE, Norley S, Goudsmit J, Schulz TF.

J Virol. 2000 Feb;74(3):1572-7.

47.

Decline of simian immunodeficiency virus (SIV)-specific cytotoxic T lymphocytes in the peripheral blood of long-term nonprogressing macaques infected with SIVmac32H-J5.

Geretti AM, Hulskotte EG, Dings ME, van Baalen CA, van Amerongen G, Norley SG, Boers P, Gruters R, Osterhaus AD.

J Infect Dis. 1999 Oct;180(4):1133-41.

PMID:
10479140
48.

Simian immunodeficiency virus (SIV) from sun-tailed monkeys (Cercopithecus solatus): evidence for host-dependent evolution of SIV within the C. lhoesti superspecies.

Beer BE, Bailes E, Goeken R, Dapolito G, Coulibaly C, Norley SG, Kurth R, Gautier JP, Gautier-Hion A, Vallet D, Sharp PM, Hirsch VM.

J Virol. 1999 Sep;73(9):7734-44.

49.

Why are the natural hosts of SIV resistant to AIDS?

Norley S, Beer B, Holzammer S, zur Megede J, Kurth R.

Immunol Lett. 1999 Mar;66(1-3):47-52.

PMID:
10203033
50.

Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees.

Bogers WM, Koornstra WH, Dubbes RH, ten Haaft PJ, Verstrepen BE, Jhagjhoorsingh SS, Haaksma AG, Niphuis H, Laman JD, Norley S, Schuitemaker H, Goudsmit J, Hunsmann G, Heeney JL, Wigzell H.

J Gen Virol. 1998 Dec;79 ( Pt 12):2895-903.

PMID:
9880002

Supplemental Content

Loading ...
Support Center